|Bid||0.00 x 1000|
|Ask||0.00 x 2900|
|Day's range||38.22 - 39.71|
|52-week range||24.10 - 42.37|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||15.18|
|Earnings date||27 Apr 2021 - 03 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||43.36|
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based medical solutions, for an upfront cash payment of $1.07 billion, subject to closing adjustments. BPEA will retain ownership of the Lumenis global aesthetics and ophthalmology businesses. With 2021 net sales anticipated to be approximately $200 million, the Lumenis surgical business includes premier laser systems, fibers and accessories used for urology and otolaryngology procedures. Foundational to its urology portfolio is the proprietary MOSES™ technology, which has demonstrated differentiated clinical outcomes and efficiency in the management of patients with kidney stones.